Pharmacogenomics in the treatment of mood disorders: Strategies and Opportunities for personalized psychiatry

AbstractPersonalized medicine (personalized psychiatry in a specific setting) is a new model towards individualized care, in which knowledge from genomics and other omic pillars (microbiome, epigenomes, proteome, and metabolome) will be combined with clinical data to guide efforts to new drug development and targeted prescription of the existing treatment options. In this review, we summarize pharmacogenomic studies in mood disorders that may lay the foundation towards personalized psychiatry. In addition, we have discussed the possible strategies to integrate data from omic pillars as a future path to personalized psychiatry. So far, the progress of uncovering single nucleotide polymorphisms (SNPs) underpinning treatment efficacy in mood disorders (e.g., SNPs associated with selective serotonin re-uptake inhibitors or lithium treatment response in patients with bipolar disorder and major depressive disorder) are encouraging, but not adequate. Genetic studies have pointed to a number of SNPs located at candidate genes that possibly influence response to; (a) antidepressantsCOMT,HTR2A,HTR1A,CNR1,SLC6A4, NPY,MAOA,IL1B,GRIK4,BDNF,GNB3,FKBP5,CYP2D6,CYP2C19, andABCB1 and (b) mood stabilizers (lithium)5-HTT,TPH,DRD1,FYN,INPP1,CREB1,BDNF,GSK3 β,ARNTL,TIM,DPB,NR3C1,BCR,XBP1, andCACNG2. We suggest three alternative and complementary strategies to implement knowledge gained from pharmacogenomic studies. The first strategy can be to implement diagnostic, therapeutic, or prognostic gene...
Source: EPMA Journal - Category: International Medicine & Public Health Source Type: research